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Background
The involvement of the endothelin signaling system dur-
ing orthodontic tooth movement has not been explained
yet. Therefore, the aim of this study was to determine the
role of endothelins ET-1, ET-2 and ET-3 and both receptor
subtypes ETA and ETB during all the three phases of ortho-
dontic tooth movement in a rat model.
Methods
The study was performed on male Wistar rats (n = 85).
Orthodontic tooth movement was induced by a closed
coil spring (F = 25 cN), which was placed between the
upper left first molar and the upper incisors. The effects of
the endothelin system were investigated using tezosentan,
a non-selective endothelin antagonist, and TBC3214, a
highly selective ETA antagonist. Measurements of the dis-
tance between the upper left first molar and the ipsilateral
incisor were performed on a weekly basis for 6 consecu-
tive weeks. After that, the animals were sacrificed and tis-
sue samples of the maxilla were taken for further
biochemical and histological evaluations.
Results
Tezosentan increased tooth movement (p < 0.01). The
opposite effect was shown using TBC3214, which
decreased tooth movement (p < 0.01). On day 14, gene
expression levels for ET-1 (p < 0.05) and ET-3 (p < 0.001)
were increased compared to day 0. On day 28, a down-
regulation of ET-3 was observed when compared to day 0
(p < 0.001). On day 42, ET-1 (p < 0.001) and ET-3 (p <
0.01) gene expression levels were strongly up-regulated,
while ET-2 gene expression level was down-regulated (p <
0.01) when compared with day 0. The immunoreactivity
of ETA and ETB significantly decreased on day 14 (p <
0.001) and increased on day 28 (p < 0.001). Alveolar
bone volume was significantly higher in the TBC3214
group compared to the appliance only group (p < 0.001).
Osteoclast volume was significantly lower in the TBC3214
group compared to the appliance only group (p < 0.05).
Conclusion
ET-1 and ET-3 are the endothelin isopeptides, which are
involved in all three phases of orthodontic tooth move-
ment. However, ET-1 is the predominant physiological
form functioning during the late phase of orthodontic
tooth movement. Gene and protein expression levels indi-
cate that the major signaling pathway during the late
phase of orthodontic tooth movement mainly involves
ETA receptors. During this phase ET-1 increases osteoclas-
tic bone resorption via ETA.
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